ReviR Therapeutics to Present AI-Driven RNA-Targeting Small Molecule Therapies at BIOLIGN 2026 Guangzhou and IDC2026 Suzhou Conferences
ReviR Therapeutics
Innovative Drug Developer
May 19-20, 2026, "Biopharmaceutical Innovation Pioneers Conference"Will be held in Guangzhou, during the same period, "IDC2026 7th Chemical Innovative Drug R&D and AI Drug Design Forum"Will be held in Suzhou. ReviR Therapeutics has been invited to attend and will share at two conferences respectively."Practical Applications of AI-Empowered Small Molecule Modulation RNA Innovative Therapies, welcome scholars and experts to come for communication and discussion.
About ReviR Therapeutics (ReviR Therapeutics, Inc.)
ReviR Therapeutics is a global biotechnology company at the clinical stage, dedicated to combining AI technology with RNA biology to develop highly specific, effective, and safe disease-modifying therapies. With the deep technical accumulation of its self-developed platform VoyageR, ReviR Therapeutics has established multiple innovative drug pipelines in the fields of neurological diseases and autoimmune disorders. Its leading small-molecule drug candidate, RTX-117, is currently advancing in clinical trials for Charcot-Marie-Tooth disease (CMT) / Vanishing White Matter disease (VWM), while continuously expanding into new indications.
Official Website: www.revirtx.com
Contact for inquiries: info@revirtx.com
Media/Partnership Contact: pr@revirtx.com